​

Celldex Therapeutics (CLDX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

CLDX Stock Forecast

Celldex Therapeutics (CLDX) stock forecast, based on 18 Wall Street analysts, predicts a 12-month average price target of $21.00, with a high of $21.00 and a low of $21.00. This represents a -24.87% decline from the last price of $27.95.

$20 $26 $32 $38 $44 $50 High: $21 Avg: $21 Low: $21 Last Closed Price: $27.95

CLDX Stock Rating

Celldex Therapeutics stock's rating consensus is Buy, based on 18 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 14 Buy (77.78%), 3 Hold (16.67%), 1 Sell (5.56%), and 0 Strong Sell (0.00%).

Buy
Total 18 1 3 14 0 Strong Sell Sell Hold Buy Strong Buy

CLDX Price Target Upside V Benchmarks

TypeNameUpside
StockCelldex Therapeutics-24.87%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-23
Avg Price Target-$23.00$30.67
Last Closing Price$27.95$27.95$27.95
Upside/Downside--17.71%9.73%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Dec, 251122-116
Nov, 252112-116
Oct, 252102--14
Sep, 252112--15
Aug, 252112--15
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 11, 2025Barclays$21.00$22.67-7.37%-24.87%
Oct 13, 2025Barclays$25.00$26.77-6.61%-10.55%
Mar 20, 2025Morgan Stanley$46.00$19.88131.39%64.58%
Oct 29, 2024Joseph PantginisH.C. Wainwright$80.00$27.12194.99%186.23%
Sep 25, 2024Derek ArchilaWells Fargo$44.00$36.0222.15%57.42%
Jun 17, 2024Alex ThompsonStifel Nicolaus$58.00$34.9166.14%107.51%
Nov 10, 2023Derek ArchilaWells Fargo$27.00$25.784.73%-3.40%
Nov 11, 2022Guggenheim$63.00$39.8957.93%125.40%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 13, 2025BarclaysUnderweightinitialise
Mar 20, 2025Morgan StanleyOverweightinitialise
Jan 08, 2025CitigroupBuyBuyhold
Oct 29, 2024H.C. WainwrightBuyBuyhold
Oct 28, 2024Cowen & Co.BuyBuyhold
Oct 28, 2024Wolfe ResearchBuyBuyhold
Oct 28, 2024GuggenheimBuyBuyhold
Oct 07, 2024CitigroupBuyinitialise
Sep 30, 2024Goldman SachsNeutralinitialise
Sep 27, 2024Leerink PartnersMarket Performdowngrade

Financial Forecast

EPS Forecast

$-5 $-4 $-3 $-2 $-1 $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.02$-1.64$-2.62$-2.92$-2.45----
Avg Forecast$-1.77$-1.64$-2.38$-2.80$-2.45$-3.28$-3.79$-3.75$-1.07
High Forecast$-0.91$-0.84$-1.61$-2.60$-2.35$-2.93$-2.85$-3.15$-0.61
Low Forecast$-3.21$-2.97$-3.71$-2.95$-2.59$-3.55$-4.82$-4.28$-1.74
Surprise %14.12%-10.08%4.29%-----

Revenue Forecast

$0 $100M $200M $300M $400M $500M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$7.42M$4.65M$2.36M$6.88M$7.02M----
Avg Forecast$4.20M$5.34M$988.00K$4.11M$6.83M$4.00M$2.84M$51.13M$328.93M
High Forecast$6.82M$8.67M$1.41M$4.95M$8.32M$5.95M$2.85M$76.03M$489.11M
Low Forecast$2.63M$3.34M$742.71K$3.22M$5.67M$2.68M$2.82M$34.22M$220.10M
Surprise %76.62%-12.90%138.56%67.57%2.80%----

Net Income Forecast

$-250M $-200M $-150M $-100M $-50M $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-59.78M$-70.51M$-122.78M$-141.43M$-157.86M----
Avg Forecast$-85.92M$-79.46M$-86.68M$-141.43M$-119.81M$-157.14M$-185.74M$-180.08M$-51.60M
High Forecast$-44.15M$-40.83M$-69.35M$-113.14M$-114.06M$-142.17M$-138.09M$-152.63M$-29.41M
Low Forecast$-155.65M$-143.95M$-104.02M$-169.71M$-125.56M$-172.12M$-233.39M$-207.53M$-84.26M
Surprise %-30.42%-11.26%41.64%-31.76%----

CLDX Forecast FAQ

Is Celldex Therapeutics stock a buy?

Celldex Therapeutics stock has a consensus rating of Buy, based on 18 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 14 Buy, 3 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Celldex Therapeutics is a favorable investment for most analysts.

What is Celldex Therapeutics's price target?

Celldex Therapeutics's price target, set by 18 Wall Street analysts, averages $21 over the next 12 months. The price target range spans from $21 at the low end to $21 at the high end, suggesting a potential -24.87% change from the previous closing price of $27.95.

How does Celldex Therapeutics stock forecast compare to its benchmarks?

Celldex Therapeutics's stock forecast shows a -24.87% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Celldex Therapeutics over the past three months?

  • December 2025: 6.25% Strong Buy, 75.00% Buy, 12.50% Hold, 0% Sell, 6.25% Strong Sell.
  • November 2025: 12.50% Strong Buy, 68.75% Buy, 12.50% Hold, 0% Sell, 6.25% Strong Sell.
  • October 2025: 14.29% Strong Buy, 71.43% Buy, 14.29% Hold, 0% Sell, 0% Strong Sell.

What is Celldex Therapeutics’s EPS forecast?

Celldex Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-3.28, marking a 33.88% increase from the reported $-2.45 in 2024. Estimates for the following years are $-3.79 in 2026, $-3.75 in 2027, and $-1.07 in 2028.

What is Celldex Therapeutics’s revenue forecast?

Celldex Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $4M, reflecting a -42.96% decrease from the reported $7.02M in 2024. The forecast for 2026 is $2.84M, followed by $51.13M for 2027, and $328.92M for 2028.

What is Celldex Therapeutics’s net income forecast?

Celldex Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-157M, representing a -0.45% decrease from the reported $-158M in 2024. Projections indicate $-186M in 2026, $-180M in 2027, and $-51.598M in 2028.